Publications by authors named "D Bafaloukos"
Checkpoint inhibitor myocarditis is a rare but life-threatening toxicity of immunotherapy, occasionally manifesting as persistent troponin elevation. Dual checkpoint blockade with ipilimumab and nivolumab has been found to induce immune-related myocarditis in patients with metastatic melanoma. We herein report a case of smoldering immune-related myocarditis in a 54-year-old male after a single infusion of nivolumab plus ipilimumab as adjuvant treatment for completely resected stage IV melanoma.
View Article and Find Full Text PDFThe B-Raf proto-oncogene, serine/threonine kinase (BRAF)/ mitogen-activated protein kinase kinase (MEK) targeting agents have become the treatment of choice for BRAF-mutated melanoma during the last decade. However, it is possible that some long-term adverse events of these drugs have not yet been reported. A case of bilateral spontaneous, non-traumatic, supraspinatus tendon rupture in a 65-year-old Caucasian male suffering metastatic melanoma under prolonged and successful combination treatment with dabrafenib plus trametinib is presented.
View Article and Find Full Text PDFTen-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.
Breast
February 2024
Article Synopsis
- Dose-dense sequential (dds) chemotherapy has positively impacted long-term survival rates in early breast cancer patients, as shown in the observational trial HE 10/10.
- The study analyzed the role of tumor infiltrating lymphocytes (TILs) and CD8 lymphocytes in predicting outcomes, finding that higher levels are linked to better survival.
- With a median follow-up of over 10 years, the study reported disease-free survival (DFS) at 78.4% and overall survival (OS) at 81.7%, highlighting the regimen's efficacy and safety.
Article Synopsis
- This study focused on collecting real-world evidence about treatment patterns and patient profiles for advanced melanoma in Greece between January 2015 and January 2018, using data from six oncology clinics.
- A total of 225 patients were included, with a median age of 62.6 years; most were diagnosed with metastatic disease and had common metastatic sites in the lungs, lymph nodes, and liver.
- Treatment options mostly involved targeted therapy (53.3%) and immunotherapy (45.3%), with the most common first-line regimens being combinations of BRAF inhibitors with MEK inhibitors and anti-PD-1 monotherapy.
Background/aim: Nivolumab is an FDA-approved immune checkpoint inhibitor (ICI) for patients with advanced, pre-treated non-small cell lung cancer (NSCLC). However, treatment profiles and patient outcomes often differ in routine clinical practice while the financial impact of approved therapies is largely unknown. In this study, we investigated the efficacy, tolerability, and economic impact of nivolumab in real-world settings (RWS) in Greece.
View Article and Find Full Text PDF